AstraZeneca Results Presentation Deck
Oncology
Total Revenue ($m)
1,600
1,400
1,200
1,000
800
600
400
200
☐EM
0
EROW
■ Europe
■US
Q2
390
234
244
438
Tagrisso
12% growth at CER to $2,915m in H1 2023
Q3
2021
315
232
259
441
Q4
325
245
258
486
Q1
406
207
252
439
Q2
400
231
256
513
2022
Q3
406
203
268
521
Q4
356
206
245
535
38 Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
CER = constant exchange rates; EM = Emerging Markets; EROW = Established Rest of World.
Q1
444
202
257
521
2023
Q2
408
218
284
581
Total Revenue ($m)
1,200
1,000
800
600
400
200
☐EM
0
EROW
Europe
US
Q2
75
106
118
305
Imfinzi
57% growth at CER to $1,976m in H1 2023
Q3
2021
78
101
120
319
Q4
65
101
138
330
Q1
58
101
125
315
Q2
APPENDIX | H1 2023 Product Performance
75
104
142
374
2022
Q3
90
99
135
413
Q4
63
97
142
450
Q1
81
134
163
522
2023
Q2
102
222
176
576View entire presentation